An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Epidiolex

Chemical Namecannabidiol
Dosage FormSolution (oral; 100 mg/mL)
Drug ClassMiscellaneous
SystemNervous
CompanyGreenwich Biosciences
Approval Year2018

Indication

  • Epidiolex is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous sclerosis complex in patients 1 year of age and older.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Epidiolex (cannabidiol) Prescribing Information2020Greenwich Biosciences
Document TitleYearSource
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome.2019NICE
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome.2019NICE
Document TitleYearSource
Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety.2020CNS Drugs
Cannabis-based products for pediatric epilepsy: A systematic review2019Epilepsia
Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta‑analysis.2018Drugs
Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis.2018CNS Drugs